A Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled Phase III Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus
Latest Information Update: 14 Mar 2024
At a glance
- Drugs TNM 002 (Primary) ; Tetanus immune globulin
- Indications Tetanus
- Focus Pharmacodynamics; Registrational
- Sponsors Trinomab Biotech
Most Recent Events
- 31 Oct 2023 Status changed from active, no longer recruiting to completed.
- 17 May 2023 Status changed from recruiting to active, no longer recruiting.
- 19 Jan 2023 Status changed from not yet recruiting to recruiting.